Reuters logo
3 months ago
BRIEF-Janssen Research & Development submits supplemental application to FDA to update prescribing information for Xarelto
April 28, 2017 / 8:49 PM / 3 months ago

BRIEF-Janssen Research & Development submits supplemental application to FDA to update prescribing information for Xarelto

1 Min Read

April 28 (Reuters) - Johnson & Johnson-

* Janssen Research & Development says it has submitted supplemental new drug application to u.s. Fda to update prescribing information for xarelto

* Janssen seeks to update prescribing info for xarelto to add 10 mg dose to reduce patients' risk of recurrent venous thromboembolism Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below